Bristol won’t seek faster Opdivo/Yervoy lung cancer approval

Bristol won’t seek faster Opdivo/Yervoy lung cancer approval Bristol won’t seek faster Opdivo/Yervoy lung cancer approval:- Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for a combination of its two immunotherapy drugs as an initial treatment for lung cancer. Shares of Bristol, which […]